about
Extracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsExtracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsExtracorporeal photopheresis versus alternative treatment for chronic graft-versus-host disease after haematopoietic stem cell transplantation in paediatric patientsAllogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials.Successful treatment of oral lesions of chronic lichenoid graft-vs.-host disease by the addition of low-level laser therapy to systemic immunosuppression.Clinical grading in chronic graft-versus-host disease: is it time for change?Role of extracorporeal photochemotherapy in patients with refractory chronic graft-versus-host disease.Use of recombinant factor VIIa in uncontrolled gastrointestinal bleeding after hematopoietic stem cell transplantation among patients with thrombocytopeniaProspective predictors of return to work in the 5 years after hematopoietic cell transplantationChronic graft-versus-host disease (GVHD) in children.Weekly rituximab followed by monthly rituximab treatment for steroid-refractory chronic graft-versus-host disease: results from a prospective, multicenter, phase II studyExtracorporeal photopheresis in chronic graft-versus-host disease.Factors that contribute to long-term survival in patients with leukemia not in remission at allogeneic hematopoietic cell transplantation.How we treat chronic graft-versus-host disease.Immunotherapy of cancer by active vaccination: does allogeneic bone marrow transplantation after non-myeloablative conditioning provide a new option?Extracorporeal photopheresis for graft-versus-host disease: the role of patient, transplant, and classification criteria and hematologic values on outcome-results from a large single-center study.Chronic graft-versus-host disease: where do we go from here?Topical corticosteroid therapy for cicatricial conjunctivitis associated with chronic graft-versus-host disease.Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in MiceChronic graft versus host disease.Mechanism of action of extracorporeal photochemotherapy in chronic graft-versus-host disease.New approaches for preventing and treating chronic graft-versus-host disease.Influence of T-cell depletion on chronic graft-versus-host disease: results of a multicenter randomized trial in unrelated marrow donor transplantation.Rituximab for steroid-refractory chronic graft-versus-host disease.Acute graft versus host disease.Chronic graft-versus-host disease: where is promise for the future?Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host diseaseExtracorporeal photopheresis in graft-versus-host disease.U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease.Evaluation of mycophenolate mofetil for initial treatment of chronic graft-versus-host disease.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Complications of allogeneic hematopoietic stem cell transplantation.An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.Multipotent Mesenchymal Stromal Cells for the Prophylaxis of Acute Graft-versus-Host Disease-A Phase II Study.T cell transduction and suicide with an enhanced mutant thymidine kinase.Evaluation for synergistic suppression of T cell responses to minor histocompatibility antigens by chloroquine in combination with tacrolimus and a rapamycin derivative, SDZ-RAD.Sclerodermatous chronic graft-versus-host disease--a report of four pediatric cases.Risk factors for vancomycin-resistant enterococcus bacteremia and its influence on survival after allogeneic hematopoietic cell transplantation.Donor T-cell chimerism and early post-transplant cytomegalovirus viremia in patients treated with myeloablative allogeneic hematopoietic stem cell transplant.Identification of risk factors for bronchiolitis obliterans syndrome after reduced toxicity conditioning before hematopoietic cell transplantation.
P2860
Q24187102-1CE48318-3827-47A0-AA95-BDB872910596Q24200272-406D7A89-A03B-4738-881C-DBCDC9C2DD0DQ24202963-B283946E-B65F-4CEA-AEE8-FAF9B5C9AE5EQ30997153-D3F1F67F-2373-4B68-B5F0-01E78C9FBA50Q31047568-2C9B3B6F-CAF0-4742-BCE6-7854D3471D8FQ33343489-149A9DB9-B9AC-4B01-A4E3-78D6CBEF9668Q33367386-52FF75FF-669A-4601-8199-1565E4D14CE2Q33429950-83FA290D-C484-4E64-BCE0-160AC11E0E0CQ33786982-6E98F87D-56AC-47B9-9DFA-B3A7007AB0ADQ33857680-26CD2AAD-C881-4D09-8E5E-31D339B5209CQ34255166-4CA9BED2-1262-4708-8F6B-34006CA233D7Q34662907-9054F28C-F934-4CC2-AE1F-B9BEFBE399E2Q34871703-4C915DA1-541B-4428-B10B-1A79A8730005Q35004923-6C99E44F-AB4B-4F2B-9263-5B4BFDFE5EEDQ35142329-251CF009-CF5E-4B5A-BB19-DBCECBB925C5Q35495340-FABC2C4F-7767-4CCF-8122-A15402012512Q35638378-BAD3CA00-53EA-41B9-B4D6-9B01606BCCB0Q35719211-ABDF43DD-66CE-4840-853A-BAD7BC33F681Q35766798-5416206B-5C6C-4BBB-9DC6-740A799CCA7AQ35772587-2B54E1BC-CFC7-40D7-AB4A-9BFA697314C6Q35815967-24FEDBB3-E6C2-4BB5-9A84-1B1B39C35D18Q35847596-72F79FB5-8585-4388-965F-5F22D691BDF1Q35848407-50F03209-7D9B-445E-A008-760DA0D6BC6DQ35848933-5D0BEC6B-3A50-421A-AF19-B80494880DD1Q36059671-87374FEF-E1F7-44A8-99CA-7D383B646565Q36180596-8F350622-CABF-4083-A638-DF1CC16879C2Q36505142-08CF431D-47C1-45D9-96DC-DFE616F3BBBEQ37051405-F631BDA4-6747-4104-AD41-10A07DEC3A3EQ37074253-E2FC7E34-64E0-40E5-B72C-1A68B3B721DAQ37201939-30EA1ABF-9D78-4749-ABA4-AD7099764DA6Q38136748-87C5E6B6-109A-464A-BF9A-F9503E17821DQ38217938-6079F0EB-8880-41A0-B6B1-DEF9D2A64938Q40204811-7B179647-5B8F-4D71-9B0D-92004598E6F3Q40235917-7577F026-26CF-42F1-AE1F-8AAF72D871ADQ40728110-AC446BCB-D44D-4FD5-A21A-CCC9D7B3B826Q41916562-E0DA5FB0-EAA7-44BA-A7C1-649C78910A1BQ42170529-4CF3FDCB-A0D4-4959-8949-8CD39840ABF3Q42202379-55E3D0A9-D7C1-49EA-9AC9-988A02DC17D1Q42240100-B4C3B34D-1495-4F93-8C9D-8105AF25C294Q42276555-9EB2B7FF-062E-4A40-BF28-00E81D6200F0
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի մարտին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
How I treat chronic graft-versus-host disease.
@ast
How I treat chronic graft-versus-host disease.
@en
How I treat chronic graft-versus-host disease.
@nl
type
label
How I treat chronic graft-versus-host disease.
@ast
How I treat chronic graft-versus-host disease.
@en
How I treat chronic graft-versus-host disease.
@nl
prefLabel
How I treat chronic graft-versus-host disease.
@ast
How I treat chronic graft-versus-host disease.
@en
How I treat chronic graft-versus-host disease.
@nl
P356
P1433
P1476
How I treat chronic graft-versus-host disease.
@en
P2093
Vogelsang GB
P304
P356
10.1182/BLOOD.V97.5.1196
P407
P577
2001-03-01T00:00:00Z